Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimens. (Q54454128)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimens (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

8

Vania Vezzosi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

7

Simonetta Bianchi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

4

Jacopo Nori

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1

Tommaso Susini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

12

Gianfranco Scarselli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Giulia Marini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Simone Olivieri

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Cecilia Molino

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Milena Paglierani

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Massimo Giachi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Elena Borrani

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

17 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

234-239

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

7 January 2021

Testing for HER2 status

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplification and comparison with p185(HER2/neu) protein expression in breast cancer drill biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Quantitative PCR--new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Current diagnostic methods of HER-2/neu detection in breast cancer with special regard to real-time PCR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.067

10.1016/J.YGYNO.2009.10.067

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19919879%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference